Analyst Ratings for [ACAD] ACADIA Pharmaceuticals Inc.

2/11/25	Initiated	Hold	X
ACAD ACADIA Pharmaceuticals Deutsche Bank
$22
1/3/25	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Guggenheim
$23 $20
10/10/24	Resumed	Mkt Perform	X
ACAD ACADIA Pharmaceuticals Raymond James
8/7/24	Downgrades	Overweight Eq-Weight	X
ACAD ACADIA Pharmaceuticals Morgan Stanley
$28 $20
6/27/24	Initiated	Outperform	X
ACAD ACADIA Pharmaceuticals BMO Capital Markets
$31
3/12/24	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Mizuho
$39 $25
3/12/24	Reiterated	Buy	X
ACAD ACADIA Pharmaceuticals Needham
$36 $32
1/30/24	Initiated	Outperform	X
ACAD ACADIA Pharmaceuticals Robert W. Baird
$40
1/24/24	Upgrades	Hold Buy	X
ACAD ACADIA Pharmaceuticals Needham
$37
12/19/23	Upgrades	Eq-Weight Overweight	X
ACAD ACADIA Pharmaceuticals Morgan Stanley
$31 $40
12/14/23	Downgrades	Buy Hold	X
ACAD ACADIA Pharmaceuticals Deutsche Bank
$25
12/13/23	Initiated	Buy	X
ACAD ACADIA Pharmaceuticals Citigroup
$38
12/12/23	Initiated	Buy	X
ACAD ACADIA Pharmaceuticals Deutsche Bank
$25
11/6/23	Upgrades	Neutral Buy	X
ACAD ACADIA Pharmaceuticals Mizuho
$20 $35
1/3/23	Upgrades	Neutral Buy	X
ACAD ACADIA Pharmaceuticals Guggenheim
$22
11/4/22	Downgrades	Neutral Sell	X
ACAD ACADIA Pharmaceuticals Goldman
$15 $12
11/1/22	Initiated	Hold	X
ACAD ACADIA Pharmaceuticals Loop Capital
$17
8/8/22	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Citigroup
$19 $15
8/5/22	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Citigroup
$19 $15
6/21/22	Downgrades	Buy Underperform	X
ACAD ACADIA Pharmaceuticals Jefferies
$25 $10
6/16/22	Upgrades	Hold Buy	X
ACAD ACADIA Pharmaceuticals Jefferies
$25
3/16/22	Upgrades	Hold Buy	X
ACAD ACADIA Pharmaceuticals Canaccord Genuity
$30 $31
2/9/22	Upgrades	Neutral Buy	X
ACAD ACADIA Pharmaceuticals H.C. Wainwright
$36
1/5/22	Upgrades	Neutral Buy	X
ACAD ACADIA Pharmaceuticals Citigroup
$30
12/21/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Guggenheim
$28
11/1/21	Upgrades	Neutral Buy	X
ACAD ACADIA Pharmaceuticals Guggenheim
$23
10/14/21	Downgrades	Overweight Eq-Weight	X
ACAD ACADIA Pharmaceuticals Morgan Stanley
$20
6/10/21	Initiated	Hold	X
ACAD ACADIA Pharmaceuticals Berenberg
$29
4/7/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals H.C. Wainwright
$43 $18
4/6/21	Downgrades	Buy Hold	X
ACAD ACADIA Pharmaceuticals Canaccord Genuity
$40 $26
4/6/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Goldman
$73 $25
4/6/21	Downgrades	Buy Hold	X
ACAD ACADIA Pharmaceuticals Jefferies
$40 $21
4/6/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Mizuho
$37 $25
3/10/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals BofA Securities
3/9/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Citigroup
$66 $35
3/9/21	Downgrades	Buy Neutral	X
ACAD ACADIA Pharmaceuticals Guggenheim
3/9/21	Reiterated	Buy	X
ACAD ACADIA Pharmaceuticals H.C. Wainwright
$60 $43
3/9/21	Downgrades	Strong Buy Outperform	X
ACAD ACADIA Pharmaceuticals Raymond James
$65 $35
3/9/21	Downgrades	Buy Hold	X
ACAD ACADIA Pharmaceuticals Stifel
$68 $27
7/23/19	Reiterated	Buy	X
ACAD ACADIA Pharmaceuticals Needham
$40 $34
12/10/18	Initiated	Hold	X
ACAD ACADIA Pharmaceuticals Canaccord Genuity
$23
9/21/18	Upgrades	Neutral Overweight	X
ACAD ACADIA Pharmaceuticals Piper Jaffray
8/9/18	Reiterated	Hold	X
ACAD ACADIA Pharmaceuticals Stifel
$17 $14
8/7/18	Initiated	Hold	X
ACAD ACADIA Pharmaceuticals Stifel
$17
8/6/18	Downgrades	Overweight Neutral	X
ACAD ACADIA Pharmaceuticals Piper Jaffray

ACAD ACADIA Pharmaceuticals Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.